StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

Equities researchers at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

Several other research analysts have also recently weighed in on the stock. Piper Sandler reissued an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research report on Tuesday, September 17th. Lake Street Capital began coverage on shares of InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target for the company.

InspireMD Trading Up 0.7 %

Shares of NSPR opened at $3.00 on Friday. The firm has a market cap of $78.25 million, a P/E ratio of -4.00 and a beta of 0.98. The stock’s 50 day moving average is $2.69 and its two-hundred day moving average is $2.69. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42.

InspireMD (NYSE:NSPR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The business had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter in the previous year, the company earned ($0.15) earnings per share. Equities research analysts forecast that InspireMD will post -0.79 EPS for the current year.

Hedge Funds Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC purchased a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent reporting period. 44.78% of the stock is currently owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.